MBX Biosciences (MBX) Equity Average (2023 - 2026)

MBX Biosciences has disclosed Equity Average across 4 years of filings, most recently posting $403.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at $403.5 million, up 63.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $403.5 million (up 63.73% YoY), and the FY2025 annual result was $313.3 million, up 238.79% from the prior year.
• Equity Average came in at $403.5 million for Q1 2026 at MBX Biosciences, up from $378.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $403.5 million in Q1 2026 to a low of -$90.5 million in Q2 2024.
• The 4-year median for Equity Average is $236.9 million (2025), against an average of $167.3 million.
• Across the five-year window, Equity Average jumped 485.19% in 2024 and soared 43.11% in 2025, its largest moves.
• MBX Biosciences' Equity Average stood at -$68.6 million in 2023, then surged by 485.19% to $264.4 million in 2024, then soared by 43.11% to $378.4 million in 2025, then advanced by 6.64% to $403.5 million in 2026.
• The last three Equity Average figures came in at $403.5 million (Q1 2026), $378.4 million (Q4 2025), and $303.4 million (Q3 2025), per Business Quant data.